Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

ABSTRACT: Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

PROVIDER: PRJNA1098591 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28607796_1.fastq.gz	Fastqsanger.gz
	SRR28607796_2.fastq.gz	Fastqsanger.gz
	SRR28607797_1.fastq.gz	Fastqsanger.gz
	SRR28607797_2.fastq.gz	Fastqsanger.gz
	SRR28607798_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

Project description:Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

| PRJNA1098587 | ENA

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

Project description:Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

| PRJNA1098589 | ENA

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

Project description:Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

| PRJNA1205401 | ENA

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

Project description:Melanoma is one of the tumor types with the highest risk of brain metastasis. However, the biology of melanoma brain metastasis and the contribution of the brain immune microenvironment to the responses to therapies remain insufficiently characterized. By using preclinical models and single-cell transcriptomics, we identify a mechanism to promote antitumor immunity in melanoma brain metastasis. We show that activation of the Rela/NF-kB pathway in microglia promotes melanoma brain metastasis and that targeting this pathway elicits microglia reprogramming towards a proinflammatory phenotype that enhances antitumor immunity and reduces brain metastatic burden. Additionally, proinflammatory microglial markers in melanoma brain metastasis correlate with better responses to immune checkpoint inhibitors in patients and we show that Rela/NF-kB targeting improves responses to these therapies in the brain. Thus, we propose targeting Rela/NF-kB in activated microglia as a strategy to promote antitumor immunity and responses to immune checkpoint inhibitors in melanoma brain metastasis.

2025-02-07 | GSE285670 | GEO

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

Project description:Melanoma is one of the solid tumor types with the highest risk of brain metastasis. However, the biology of melanoma brain metastasis and the contribution of the brain immune microenvironment to the responses to therapies remain insufficiently characterized. By using preclinical models and single-cell transcriptomics, we identify microglia, as critical regulators of melanoma biology in the brain. We show that activation of the Rela/NF-kB pathway in microglia promotes melanoma brain metastasis and that targeting this pathway elicits microglia reprogramming towards a pro-inflammatory phenotype that enhances anti-tumor immunity and reduces brain metastatic burden. Additionally, canonical and pro-inflammatory microglial markers in melanoma brain metastasis correlate with better responses to immune checkpoint inhibitors in patients and we show that Rela/NF-kB targeting improves responses to these therapies in the brain. Thus, we propose targeting Rela/NF-kB in activated microglia as a strategy to promote anti-tumor immunity and to improve the response to immune checkpoint inhibitors in melanoma brain metastasis.

2025-02-07 | GSE263623 | GEO

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

2025-02-07 | GSE263622 | GEO

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

2025-02-06 | GSE263625 | GEO

Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy

Project description:In this project, we transfected MC38 cells with Flag-tagged Mbtps1 or vector control. After that, we performed immunoprecipitation–mass spectrometry analysis to search the interacting proteins of MBTPS1. In our study, We observed that the loss of membrane-bound transcription factor site-1 protease (MBTPS1) in tumor cells enhanced antitumor immunity and potentiated anti-PD-1 therapy. Mechanistic studies revealed that tumor cell-intrinsic MBTPS1 competed with USP13 for binding to STAT1, thereby disrupting USP13-dependent deubiquitination and stabilization of STAT1. MBTPS1 deficiency induced CXCR3+ CD8+ T cell infiltration by upregulating STAT1-transcribed chemokines including CXCL9, CXCL10 and CXCL11. Notably, the regulatory role of MBTPS1 in antitumor immunity operates independently of its classic function in cleaving membrane-bound transcription factors. Collectively, our results provide a theoretical basis for MBTPS1 as a potential immunotherapy target and also as a predictor of immunotherapy efficacy.

2025-04-11 | PXD053978 | Pride

Neoadjuvant chemotherapy modulates T cell responses in high-grade serous ovarian cancer metastases

Project description:Our data suggest that neoadjuvant chemotherapy enhances anti-cancer responses of T cells in peritoneal metastases of patients with high-grade serous ovarian cancer but does not decrease levels of immune checkpoint molecules, providing a rationale for sequential chemo-immunotherapy. tRNA was isolated from 35 omental tissue samples of HGSOC metastases either pre or post NACT treatment. RNASeq was performed on poly-A selected mRNA fragments, 100 b.p paired end, and strand specific, on average 40 million reads per sample.

2016-07-27 | E-GEOD-71340 | biostudies-arrayexpress

Dnase1l3 enhances antitumor immunity and suppresses tumor progression

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression

| PRJNA803220 | ENA